Seattle Genetics | Actif À Court Terme



Current Assets Changement Date
AbbVie USD 25.58B 2.2B 2024-12
Acadia Pharmaceuticals USD 870.94M 67.38M 2025-03
Agios Pharmaceuticals USD 968.62M 3.02M 2025-03
Amgen USD 26.93B 2.1B 2025-03
Astellas Pharma JPY 1.2T 2.56B 2025-03
Bayer EUR 34.83B 388M 2025-03
Biogen USD 7.63B 169.2M 2025-03
BioMarin Pharmaceutical USD 3.47B 235.48M 2025-03
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Celldex Therapeutics USD 693.76M 53.4M 2025-03
Daiichi Sankyo JPY 1.91T 66.22B 2025-03
Eisai JPY 727.66B 33.44B 2025-03
Eli Lilly USD 41.26B 8.52B 2025-03
Exelixis USD 1.4B 71.08M 2025-04
Genmab DKK 4.04B 23.82B 2025-03
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 18.08B 1.09B 2025-03
Glaxosmithkline GBP 17B 301M 2024-12
Incyte USD 3.23B 7.24M 2025-03
Insmed USD 1.4B 218.97M 2025-03
MacroGenics USD 217.49M 4.71M 2024-12
Merck USD 35.5B 3.28B 2025-03
Moderna USD 6.77B 1.33B 2025-03
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 45.86B 4.5B 2025-03
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Sanofi 44.02B 1.43B 2025-03
Sarepta Therapeutics USD 2.43B 640.93M 2025-03
Takeda JPY 2.52T 233.1B 2025-03
Teva Pharmaceutical Industries USD 11.53B 1.02B 2025-03
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12
Xencor USD 521.27M 56.33M 2025-03



Seattle Genetics Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.